Evidence map›Paper›PMID 32783398›Full record

ArticleEMBO reports2020

The breast cancer oncogene IKKε coordinates mitochondrial function and serine metabolism.

Ruoyan Xu, William Jones, Ewa Wilcz-Villega, Ana Sh Costa, Vinothini Rajeeve, Robert B Bentham, Kevin Bryson, Ai Nagano, Busra Yaman, Sheila Olendo Barasa and 6 more

Open access · hybridAbstract read
In one paragraph

Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Ruoyan Xu *Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
William Jones *Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Ewa Wilcz-VillegaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Ana Sh CostaMedical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.
Vinothini RajeeveCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Robert B BenthamDepartment of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, UK.
Kevin BrysonDepartment of Computer Sciences, University College London, London, UK.
Ai NaganoCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Busra YamanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Sheila Olendo BarasaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Yewei WangCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Claude ChelalaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Pedro CutillasCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Gyorgy SzabadkaiDepartment of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, UK.ORCID 0000-0002-3006-3577
Christian FrezzaMedical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.
Katiuscia BianchiCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.ORCID 0000-0002-4549-4476
Queen Mary University of London · GBUniversity of Cambridge · GBCold Spring Harbor Laboratory · USThe Francis Crick Institute · GBUniversity College London · GBUniversity of Padua · IT

Funding

Associazione Italiana per la Ricerca sul Cancro (AIRC) IG22221Barts and the London Charity 297/2249Barts and the London Charity 467/2053Biotechnology and Biological Sciences Research Council BB/L020874/1Biotechnology and Biological Sciences Research Council BB/M006174/1Medical Research Council MC_UU_12022/6UK Research and Innovation |Biotechnology and Biological Sciences Research Council (BBSRC) BB/L020874/1UK Research and Innovation |Biotechnology and Biological Sciences Research Council (BBSRC) BB/M006174/1UK Research and Innovation| Medical Research Council (MRC) MRC_MC_ UU_12022/6University College London COMPLeX/British Heart Foundation Fund SP/08/004Wellcome TrustWellcome Trust (WT) 097815/Z/11/Z
6 · The paper itself

Abstract

IκB kinase ε (IKKε) is a key molecule at the crossroads of inflammation and cancer. Known to regulate cytokine secretion via NFκB and IRF3, the kinase is also a breast cancer oncogene, overexpressed in a variety of tumours. However, to what extent IKKε remodels cellular metabolism is currently unknown. Here, we used metabolic tracer analysis to show that IKKε orchestrates a complex metabolic reprogramming that affects mitochondrial metabolism and consequently serine biosynthesis independently of its canonical signalling role. We found that IKKε upregulates the serine biosynthesis pathway (SBP) indirectly, by limiting glucose-derived pyruvate utilisation in the TCA cycle, inhibiting oxidative phosphorylation. Inhibition of mitochondrial function induces activating transcription factor 4 (ATF4), which in turn drives upregulation of the expression of SBP genes. Importantly, pharmacological reversal of the IKKε-induced metabolic phenotype reduces proliferation of breast cancer cells. Finally, we show that in a highly proliferative set of ER negative, basal breast tumours, IKKε and PSAT1 are both overexpressed, corroborating the link between IKKε and the SBP in the clinical context.

Indexed as

Breast NeoplasmsI-kappa B KinaseMitochondriaFemaleHumansOncogenesSerineI-kappa B KinaseSerineATF4breast cancerIKKεmitochondrial metabolismserine biosynthesis

Identifiers

PMID32783398
PMCPMC7116048
OpenAlexW3048440967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.